Motley Fool Wealth Management LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 6.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,869 shares of the medical research company’s stock after selling 1,966 shares during the period. Motley Fool Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $13,370,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in TMO. GAMMA Investing LLC raised its stake in shares of Thermo Fisher Scientific by 60,610.9% in the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company’s stock valued at $1,203,859,000 after acquiring an additional 2,415,346 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of Thermo Fisher Scientific by 86.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company’s stock valued at $1,604,338,000 after acquiring an additional 1,433,444 shares in the last quarter. Nuveen LLC bought a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $532,360,000. Kovitz Investment Group Partners LLC raised its stake in shares of Thermo Fisher Scientific by 1,905.4% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company’s stock valued at $469,889,000 after acquiring an additional 858,193 shares in the last quarter. Finally, Farallon Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 73.8% in the 4th quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company’s stock valued at $641,577,000 after acquiring an additional 523,800 shares in the last quarter. 89.23% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on TMO. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 23rd. Barclays raised their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an “equal weight” rating in a report on Thursday, July 24th. HSBC reaffirmed a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Wells Fargo & Company lowered their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. Finally, Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $593.00.
Insider Buying and Selling at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $52,037,916.68. The trade was a 7.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,400 shares of company stock valued at $8,345,792. Corporate insiders own 0.33% of the company’s stock.
Thermo Fisher Scientific Price Performance
Thermo Fisher Scientific stock opened at $461.34 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market capitalization of $174.21 billion, a PE ratio of 26.68, a price-to-earnings-growth ratio of 2.46 and a beta of 0.74. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The business has a 50 day simple moving average of $426.80 and a 200 day simple moving average of $462.63.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. Thermo Fisher Scientific’s revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the company earned $5.37 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is presently 9.95%.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
- Five stocks we like better than Thermo Fisher Scientific
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Dividend Stocks Raising Payouts—and Backing It Up With Results
- What Are Dividend Champions? How to Invest in the Champions
- 3 Stocks With Monopoly Power—and Minimal Competition
- Election Stocks: How Elections Affect the Stock Market
- Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.